MERCK & CO, INC. for MERCK & CO INC

Taxation/Internal Revenue Code TAX

Issues related to, Tax Reform, Generally; Tax Cuts and Jobs Act of 2017 (P.L. 115-97)

Contacted: Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Copyright/Patent/Trademark CPT

Issues relating to, Intellectual Property; US-Mexico-Canada Agreement.

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE; Health & Human Services, Dept of (HHS)

Health Issues HCR

H.R. 3, Lower Drug Costs Now Act of 2019, including provisions relating to international reference pricing H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act H.R. 2296, More Efficient Tools to Realize Information for Consumers Act H.R. 4100/S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. including provisions relating to Anti-microbial Resistance H.R. 4455, Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 H.R. 4629, Star Rating for Biosimilars Act H.R. 5076, Protecting Seniors Through Immunization Act of 2019 H.R. 6197, Increasing Access to Biosimilars Act of 2020 H.R. 8061, Community Immunity During COVID-19 Act of 2020 S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act S. 1895, Lower Health Care Costs Act S. 2543, Prescription Drug Pricing Reduction Act of 2019 Issues relating to, 340B Reforms; 340B program integrity; 340B of the Public Health Services Act; Drug pricing; Anti-microbial Resistance; General Pharmaceutical issues transparency, formulary design, prescription drug coverage; Biosimiliars; Cost and value of medicines; Maternal Health; Vaccines; Adult vaccines and immunizations; Supply chain; Coronavirus stimulus funding; HIV; Rebate pass through; COVID-19 vaccines; Vaccines catch up; Proposed rule on Electronic Distribution of Prescribing Information for Human Prescription Drugs, Including Biological Products (79 Fed. Reg. 75,506-75,527, December 18, 2014); Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146)

Contacted: Health & Human Services, Dept of (HHS); SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Bills named: S. 2543 (116th), H.R. 5076 (116th), S. 1895 (116th), H.R. 3 (116th), H.R. 2069 (116th), S. 474 (116th), H.R. 4629 (116th), H.R. 4597 (116th), H.R. 4100 (116th), H.R. 6197 (116th), S. 1712 (116th), H.R. 8061 (116th), H.R. 2296 (116th), H.R. 4455 (116th), S. 1209 (116th)

Medicare/Medicaid MMM

H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019 S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019, including provisions relating to AMP cap and Medicare Part D rebate Issues relating to, Medicaid; Medicare; Medicare Part B; 340B reforms; 340B program integrity; 340B of the Public Health Services Act; Medicare Part D; Drug Pricing; Center for Medicare and Medicaid demonstrations; Part D inflationary rebate; International pricing reference.

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 2543 (116th), H.R. 107 (116th), S. 62 (116th), H.R. 275 (116th), H.R. 1046 (116th), S. 476 (116th)